NR565 WEEK 5 ENDOCRINE CASE STUDY 2026/2027 |
Helen Smith, Alfonso Giuliani, John Jones | Answered
100/100 Points | Updated | Pass Guaranteed - A+ Graded
CASE STUDY 1: HELEN SMITH – TYPE 2 DIABETES
MANAGEMENT (Q1-15)
CASE INTRODUCTION: Helen Smith is a 58-year-old African American female who
presents to her primary care provider for a routine wellness visit. She has a BMI of 32
kg/m², blood pressure 148/92 mmHg, and reports increased thirst and nocturia (2-3
times nightly) over the past 3 months. Her father had Type 2 diabetes diagnosed at
age 55. She is currently on lisinopril 10 mg daily for hypertension. Fasting plasma
glucose is 142 mg/dL, A1C 7.8%, and eGFR 68 mL/min/1.73m². Her lipid panel shows
LDL 138 mg/dL, HDL 38 mg/dL, triglycerides 210 mg/dL.
Q1. Based on Helen's presentation and diagnostic criteria, which
statement best describes her diabetes classification?
A. Prediabetes requiring lifestyle modification only with repeat A1C in 6 months
B. Type 1 diabetes requiring immediate insulin initiation due to symptomatic
hyperglycemia
C. Type 2 diabetes mellitus meeting diagnostic criteria with A1C ≥6.5% and fasting
glucose ≥126 mg/dL [CORRECT]
D. Secondary diabetes from glucocorticoid use requiring endocrinology referral
Rationale: Helen meets ADA diagnostic criteria for Type 2 diabetes with A1C 7.8%
(threshold ≥6.5%) and fasting glucose 142 mg/dL (threshold ≥126 mg/dL). Distractor
A is incorrect because values exceed prediabetes thresholds (A1C 5.7-6.4%, FPG 100-
125 mg/dL). Distractor B is incorrect because Type 1 typically presents with DKA,
younger age, and insulin dependence; Helen's obesity, family history, and gradual
,symptom onset support Type 2. Distractor D is incorrect with no glucocorticoid
exposure history. 2026/2027 ADA guidelines emphasize confirming diagnosis with
repeat testing unless unequivocal hyperglycemia with classic symptoms is present.
Correct Answer: C
Q2. What is the most appropriate first-line pharmacotherapy for
Helen's Type 2 diabetes?
A. Initiate basal insulin glargine 10 units at bedtime to achieve rapid glycemic control
B. Start metformin 500 mg twice daily with meals, titrating every 1-2 weeks toward
2000 mg/day [CORRECT]
C. Begin a GLP-1 receptor agonist (semaglutide 0.25 mg weekly) as initial
monotherapy
D. Prescribe a sulfonylurea (glipizide 5 mg daily) for immediate insulin secretion
Rationale: Metformin remains the first-line agent for Type 2 diabetes per 2026/2027
ADA Standards of Care unless contraindicated. Helen's eGFR 68 mL/min/1.73m² is
above the contraindication threshold (<30 mL/min). Distractor A is incorrect because
insulin is reserved for significant hyperglycemia (A1C >10% or symptoms) or when
oral agents fail. Distractor C is incorrect because while GLP-1 agonists are excellent
add-on agents, they are not first-line unless metformin is contraindicated or
ASCVD/CKD is present (Helen has risk factors but no established disease). Distractor
D is incorrect due to hypoglycemia risk and weight gain associated with
sulfonylureas.
Correct Answer: B
Q3. Helen returns in 4 weeks reporting nausea and diarrhea since
starting metformin. Her eGFR is now 62 mL/min/1.73m². Which action
is most appropriate?
, A. Discontinue metformin immediately and switch to insulin glargine due to renal
impairment
B. Continue current dose; GI side effects are permanent and will not improve with
time
C. Reduce metformin to 500 mg daily with largest meal, reassess in 2 weeks, and plan
slow titration [CORRECT]
D. Switch to metformin ER 1000 mg twice daily to bypass GI side effects completely
Rationale: GI side effects (nausea, diarrhea) are common with metformin initiation
but typically transient (resolve within 1-2 weeks). The appropriate strategy is dose
reduction with slow titration. Distractor A is incorrect because eGFR 62
mL/min/1.73m² is well above the discontinuation threshold (<30 mL/min); metformin
is contraindicated only at eGFR <30. Distractor B is incorrect because GI effects are
NOT permanent and improve with gradual titration. Distractor D is incorrect because
while extended-release formulations may reduce GI effects, starting at 1000 mg twice
daily would worsen symptoms; ER should also be titrated gradually from 500 mg.
Correct Answer: C
Q4. Helen is scheduled for a CT scan with iodinated contrast dye in 2
weeks. Her current eGFR is 58 mL/min/1.73m². What is the correct
metformin management?
A. Continue metformin through the procedure; contrast dye does not affect
metformin clearance
B. Hold metformin 48 hours before and 48 hours after contrast administration,
reassess renal function [CORRECT]
C. Discontinue metformin permanently and switch to a DPP-4 inhibitor before any
imaging
D. Hold metformin only on the day of the procedure and resume immediately after
Rationale: For eGFR 30-60 mL/min/1.73m², 2026/2027 guidelines recommend
holding metformin 48 hours before and after iodinated contrast, with renal function
reassessment before resuming. Distractor A is incorrect because contrast-induced
nephropathy increases lactic acidosis risk. Distractor C is incorrect because
Helen Smith, Alfonso Giuliani, John Jones | Answered
100/100 Points | Updated | Pass Guaranteed - A+ Graded
CASE STUDY 1: HELEN SMITH – TYPE 2 DIABETES
MANAGEMENT (Q1-15)
CASE INTRODUCTION: Helen Smith is a 58-year-old African American female who
presents to her primary care provider for a routine wellness visit. She has a BMI of 32
kg/m², blood pressure 148/92 mmHg, and reports increased thirst and nocturia (2-3
times nightly) over the past 3 months. Her father had Type 2 diabetes diagnosed at
age 55. She is currently on lisinopril 10 mg daily for hypertension. Fasting plasma
glucose is 142 mg/dL, A1C 7.8%, and eGFR 68 mL/min/1.73m². Her lipid panel shows
LDL 138 mg/dL, HDL 38 mg/dL, triglycerides 210 mg/dL.
Q1. Based on Helen's presentation and diagnostic criteria, which
statement best describes her diabetes classification?
A. Prediabetes requiring lifestyle modification only with repeat A1C in 6 months
B. Type 1 diabetes requiring immediate insulin initiation due to symptomatic
hyperglycemia
C. Type 2 diabetes mellitus meeting diagnostic criteria with A1C ≥6.5% and fasting
glucose ≥126 mg/dL [CORRECT]
D. Secondary diabetes from glucocorticoid use requiring endocrinology referral
Rationale: Helen meets ADA diagnostic criteria for Type 2 diabetes with A1C 7.8%
(threshold ≥6.5%) and fasting glucose 142 mg/dL (threshold ≥126 mg/dL). Distractor
A is incorrect because values exceed prediabetes thresholds (A1C 5.7-6.4%, FPG 100-
125 mg/dL). Distractor B is incorrect because Type 1 typically presents with DKA,
younger age, and insulin dependence; Helen's obesity, family history, and gradual
,symptom onset support Type 2. Distractor D is incorrect with no glucocorticoid
exposure history. 2026/2027 ADA guidelines emphasize confirming diagnosis with
repeat testing unless unequivocal hyperglycemia with classic symptoms is present.
Correct Answer: C
Q2. What is the most appropriate first-line pharmacotherapy for
Helen's Type 2 diabetes?
A. Initiate basal insulin glargine 10 units at bedtime to achieve rapid glycemic control
B. Start metformin 500 mg twice daily with meals, titrating every 1-2 weeks toward
2000 mg/day [CORRECT]
C. Begin a GLP-1 receptor agonist (semaglutide 0.25 mg weekly) as initial
monotherapy
D. Prescribe a sulfonylurea (glipizide 5 mg daily) for immediate insulin secretion
Rationale: Metformin remains the first-line agent for Type 2 diabetes per 2026/2027
ADA Standards of Care unless contraindicated. Helen's eGFR 68 mL/min/1.73m² is
above the contraindication threshold (<30 mL/min). Distractor A is incorrect because
insulin is reserved for significant hyperglycemia (A1C >10% or symptoms) or when
oral agents fail. Distractor C is incorrect because while GLP-1 agonists are excellent
add-on agents, they are not first-line unless metformin is contraindicated or
ASCVD/CKD is present (Helen has risk factors but no established disease). Distractor
D is incorrect due to hypoglycemia risk and weight gain associated with
sulfonylureas.
Correct Answer: B
Q3. Helen returns in 4 weeks reporting nausea and diarrhea since
starting metformin. Her eGFR is now 62 mL/min/1.73m². Which action
is most appropriate?
, A. Discontinue metformin immediately and switch to insulin glargine due to renal
impairment
B. Continue current dose; GI side effects are permanent and will not improve with
time
C. Reduce metformin to 500 mg daily with largest meal, reassess in 2 weeks, and plan
slow titration [CORRECT]
D. Switch to metformin ER 1000 mg twice daily to bypass GI side effects completely
Rationale: GI side effects (nausea, diarrhea) are common with metformin initiation
but typically transient (resolve within 1-2 weeks). The appropriate strategy is dose
reduction with slow titration. Distractor A is incorrect because eGFR 62
mL/min/1.73m² is well above the discontinuation threshold (<30 mL/min); metformin
is contraindicated only at eGFR <30. Distractor B is incorrect because GI effects are
NOT permanent and improve with gradual titration. Distractor D is incorrect because
while extended-release formulations may reduce GI effects, starting at 1000 mg twice
daily would worsen symptoms; ER should also be titrated gradually from 500 mg.
Correct Answer: C
Q4. Helen is scheduled for a CT scan with iodinated contrast dye in 2
weeks. Her current eGFR is 58 mL/min/1.73m². What is the correct
metformin management?
A. Continue metformin through the procedure; contrast dye does not affect
metformin clearance
B. Hold metformin 48 hours before and 48 hours after contrast administration,
reassess renal function [CORRECT]
C. Discontinue metformin permanently and switch to a DPP-4 inhibitor before any
imaging
D. Hold metformin only on the day of the procedure and resume immediately after
Rationale: For eGFR 30-60 mL/min/1.73m², 2026/2027 guidelines recommend
holding metformin 48 hours before and after iodinated contrast, with renal function
reassessment before resuming. Distractor A is incorrect because contrast-induced
nephropathy increases lactic acidosis risk. Distractor C is incorrect because
